Cook et al.(2011)99. Cook PP, Gooch M, Rizzo S. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob Agents Chemother. 2011;55(12):5597-601. |
Retrospective time-series |
861 beds medical/surgical |
graphic plots DDD/1000 PD ertapenem introduction quarter vs last quarter |
0.0 vs 18.0 (p value NP) |
10.0 vs 15.00 (p value NP) |
20.0 vs 38.0 (p value NP) |
90.0 vs 10.0 (p value NP) |
Eagye and Nicolau (2011)88. Eagye KJ, Nicolau DP. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem. J Antimicrob Chemother . 2011;66(6):1392-95. |
Retrospective time-series |
25 hospitals |
introduction year vs last year (ertapenem) first year vs last year (others) annually DDD/1000 PD |
7.27 vs 15.93 (p value NP) |
10.39 vs 15.27 (p value NP) |
NP |
303.84 vs 423.82 (p value NP) |
Goff and Mangino (2008)1212. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect. 2008;57(2):123-7. |
Retrospective time-seriess |
770 beds medical/surgical |
first year vs last year annual DDD/1000 PD |
3.4 vs 8.9 (RR = 2.61, p<0.001) |
IPM 21.5 vs 31.1 (RR=1.45, p<0.001) |
CPM 18.8 vs 63.0 |
NP |
Goldstein et al. (2009)1111. Goldstein EJ, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother . 2009;53(12):5122-6. |
Retrospective interrupted time-series |
344 beds |
introduction period median vs last period median (ertapenem) post intervention slope (others) monthly DDD/1000 PD |
8.0 vs 44.0 (p value NP) |
IPM decreased 1.28 (p=0.002) |
CPM stable (coefficients NP) |
LVX stable (coefficients NP) |
Hsu et al. (2010)1515. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH S. Network for Antimicrobial Resistance, Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother . 2010;54(3):1173-8. |
Retrospective time-series |
4 hospitals totalizing 4000 beds |
slope 3 months DDD/1000 PD throughout the entire period |
increased 0.079 (p<0.05) |
MEM increased 0.057 (p=0.03), IPM decreased 0.057 (p<0.05) |
*stable (p=0.23) |
** increased 1.677 (p<0.05) |
Lee et al. (2013)1313. Lee CM, Lai CC, Wang YY, Lee MC, Hsueh PR. Impact of susceptibility profiles of Gram-negative bacteria before and after the introduction of ertapenem at a medical center in northern Taiwan from 2004 to 2010. Diagn Microbiol Infect Dis. 2013;75(1):94-100. |
Retrospective time-series |
1130 beds |
slope annually DDD/1000 PD throughout the entire period |
increased 4.818 (p<0.001) |
MEM increased 1.557 (p<0.001), IPM increased 0.774 (p<0.001) |
CRO (p=0.2079), CAZ increased 0.862 (p<0.001), CPM (p=0.544), Cefpirome increased 0.916 (p=0.0426) |
CIP increased 0.50 (p<0.001), LVX increased 3.84 (p<0.001), MXF increased 2.674 (p<0.001) |
Lim et al. (2013)1414. Lim CL, Lee W, Lee AL, Liew LT, Nah SC, Wan CN, Chlebicki MP, Kwa AL. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH). BMC Infect Dis. 2013;13:523. |
Retrospective time-series |
NP |
first month vs last month DDD/100 PD |
0.45 vs 1.2 (p value NP) |
MEM 2.0 vs 3.2 (p value NP), IPM 1.8 vs 0.7 (p value NP) |
CRO 5.61 vs 12.5 (p value NP), CPM 5.4 vs 4.7 (p value NP) |
CIP 1.17 vs 1.3 (p value NP) |
Lima et al. (2009)1010. Lima AL, Oliveira PR, Paula AP, Dal-Paz K, Rossi F, Zumiotti AV. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol . 2009;30(5):487-90. |
Retrospective time-series |
200 beds trauma/orthopedic |
pre period vs post period DDD/1000 PD |
0.0 vs 42.6 |
IPM 46.3 vs 16.1 (p<0.001) |
NP |
NP |
Pires dos Santos et al. (2011)77. Pires dos Santos R, Jacoby T, Pires Machado D, Lisboa T, Gastal SL, Nagel FM, Kuplich NM, Konkewicz L, Gorniak Lovatto C, Pires MR, Goldani LZ. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa rates. Infect Control Hosp Epidemiol. 2011;32(6):584-90. |
Retrospective interrupted time-series |
749 beds medical/surgical |
pre period vs ertapenem period monthly DDD/100 PD |
0.05 median throughout ertapenem period |
2.6 vs 2.2 (p=0.08) |
1.1 vs 0.8 (p<0.05) |
10.1 vs 3.6 (p<0.05) |
Rodriguez-Osorio et al. (2015)66. Rodriguez-Osorio CA, Sanchez-Martinez CO, Araujo-Melendez J, Criollo E, Macias-Hernandez AE, Ponce-de-Leon A, Ponce-de-Leon S, Sifuentes-Osornio J. Impact of ertapenem on antimicrobial resistance in a sentinel group of Gram-negative bacilli: a 6 year antimicrobial resistance surveillance study. J Antimicrob Chemother . 2015; 70(3):914-21. |
Retrospective time-series |
280 beds medical/surgical |
slope 4 months DDD/1000 PD throughout the entire period |
increased 15.5 (p<0.001) |
† increased 26.6 (p<0.001) |
* Decreased 32.2 (p=0.007) |
†† decreased 38.6 (p<0.001) |
Sousa et al. (2013)1717. Sousa D, Castelo-Corral L, Gutierrez-Urbon JM, Molina F, Lopez-Calvino B, Bou G, Llinares P. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J Antimicrob Chemother . 2013;68(8):1917-25. |
Retrospective interrupted time-series |
1445 beds medical/surgical |
introduction year vs last year (ertapenem) slope change (others) monthly DDD/100 PD |
0.09 vs 2.02 (p<0.001) |
stable (p=0.56) |
CRO stable (0.082) |
stable (p=0.533) |
Yoon et al. (2014)1616. Yoon YK, Yang KS, Lee SE, Kim HJ, Sohn JW, Kim MJ. Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship. PLoS One. 2014; 9(6):e99101. |
Before-and-after |
950 beds medical/surgical |
first period vs last period monthly DDD/1000 PD |
2.7 vs 7.2 (p<0.001) |
20.7 vs 15.5 (p=0.028) |
102.2 vs 96.7 (p=0.311) |
57.7 vs 67.1 (p=0.102) |